Literature DB >> 29349795

Quality of life assumptions determine which cervical cancer screening strategies are cost-effective.

Inge M C M de Kok1, Ida J Korfage1, Wilbert B van den Hout2, Theo J M Helmerhorst3, J Dik F Habbema1, Marie-Louise Essink-Bot4, Marjolein van Ballegooijen1.   

Abstract

Quality-adjusted life years are used in cost-effectiveness analyses (CEAs). To calculate QALYs, a "utility" (0-1) is used for each health state induced or prevented by the intervention. We aimed to estimate the impact of quality of life (QoL) assumptions (utilities and durations of health states) on CEAs of cervical cancer screening. To do so, 12 alternative sets of utility assumptions were retrieved from published cervical cancer screening CEAs. Two additional sets were based on empirical QoL data that were integrally obtained through two different measures (SF-6D and EQ-5D) from eight groups of women (total n = 3,087), from invitation for screening to diagnosis with cervical cancer. Per utility set we calculated the number of quality-adjusted days lost (QADL) for each relevant health state in cervical cancer screening, by multiplying the study-specific assumed disutilities (i.e., 1-utility) with study-specific durations of the loss in QoL, resulting in 14 "QADL-sets." With microsimulation model MISCAN we calculated cost-effectiveness of 342 alternative screening programs (varying in primary screening test [Human Papillomavirus (HPV) vs. cytology], starting ages, and screening interval) for each of the 14 QADL-sets. Utilities used in CEAs appeared to differ largely. We found that ten QADL-sets from the literature resulted in HPV and two in cytology as preferred primary test. The SF-6D empirical QADL-set resulted in cytology and the EQ-5D one in HPV as preferred primary test. In conclusion, assumed utilities and health state durations determine cost-effectiveness of cervical cancer screening. Also, the measure used to empirically assess utilities can be crucial for CEA conclusions.
© 2018 UICC.

Entities:  

Mesh:

Year:  2018        PMID: 29349795     DOI: 10.1002/ijc.31265

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  4 in total

1.  Health-related Quality of Life using the EQ-5D-5L: normative utility scores in a Dutch female population.

Authors:  Marloes E Clarijs; Lindy M Kregting; Nicolien T van Ravesteyn; Linetta B Koppert; Ida J Korfage
Journal:  Qual Life Res       Date:  2022-10-20       Impact factor: 3.440

Review 2.  Cervical screening: ESGO-EFC position paper of the European Society of Gynaecologic Oncology (ESGO) and the European Federation of Colposcopy (EFC).

Authors:  Maria Kyrgiou; Marc Arbyn; Christine Bergeron; F Xavier Bosch; Joakim Dillner; Mark Jit; Jane Kim; Mario Poljak; Pekka Nieminen; Peter Sasieni; Vesna Kesic; Jack Cuzick; Murat Gultekin
Journal:  Br J Cancer       Date:  2020-06-08       Impact factor: 7.640

3.  Cost-effectiveness of HPV-based cervical screening based on first year results in the Netherlands: a modelling study.

Authors:  Eel Jansen; S K Naber; C A Aitken; H J de Koning; M van Ballegooijen; Imcm de Kok
Journal:  BJOG       Date:  2020-07-29       Impact factor: 6.531

Review 4.  Systematic Review and Meta-Analysis of Community- and Choice-Based Health State Utility Values for Lung Cancer.

Authors:  Erik F Blom; Kevin Ten Haaf; Harry J de Koning
Journal:  Pharmacoeconomics       Date:  2020-11       Impact factor: 4.981

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.